Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI:10.1016/j.curtheres.2025.100809

Mesnad S. Alyabsi PhD , Lolwah Almousa BS , Anwar H. Alqarni BS , Asma Aldawsari MS , Lubna Alnasser PhD , Adel F. Almutairi PhD

{"title":"Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends","authors":"Mesnad S. Alyabsi PhD , Lolwah Almousa BS , Anwar H. Alqarni BS , Asma Aldawsari MS , Lubna Alnasser PhD , Adel F. Almutairi PhD","doi":"10.1016/j.curtheres.2025.100809","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Continuous updates in management guidelines for type 2 diabetes mellitus (T2DM) have affected treatment patterns. In this study, we aimed to identify the prevalence of initiating various antidiabetic medications and analyze differences in patient characteristics based on the type of treatment initiated.</div></div><div><h3>Methods</h3><div>This cross-sectional study used data retrieved from the electronic medical records of the National Guard Health Affairs for all patients diagnosed with T2DM who initiated any antidiabetic therapy between January 2018 and May 2022. Patient data were presented using frequencies, percentages, means, and standard deviations where applicable. The antidiabetic classes investigated include metformin, insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter-2 inhibitors.</div></div><div><h3>Results</h3><div>In total, 433 patients with T2DM were included in this study, most of whom were females (55.66% vs 44.34%) and obese (61.20%), with a mean age of 53.29 years (SD ± 15.22). Monotherapy was the most commonly initiated approach (66.28%), with insulin being the most prescribed monotherapy (29.10%). The most frequent combination therapy was metformin and sulfonylureas (7.16%). Overall, the most initiated medication was metformin, accounting for 37.12% of all prescriptions. Additionally, there was an increasing trend in prescribing newer medications, such as GLP-1 receptor agonists (8.70%) and SGLT-2 inhibitors (11.11%), for newly diagnosed patients in 2021.</div></div><div><h3>Conclusion</h3><div>The initiation of novel antidiabetic medications has increased over the study period, reflecting recent updates in T2DM management guidelines. However, further understanding of their benefits is required for optimal patient care.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100809"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X25000347","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Continuous updates in management guidelines for type 2 diabetes mellitus (T2DM) have affected treatment patterns. In this study, we aimed to identify the prevalence of initiating various antidiabetic medications and analyze differences in patient characteristics based on the type of treatment initiated.

Methods

This cross-sectional study used data retrieved from the electronic medical records of the National Guard Health Affairs for all patients diagnosed with T2DM who initiated any antidiabetic therapy between January 2018 and May 2022. Patient data were presented using frequencies, percentages, means, and standard deviations where applicable. The antidiabetic classes investigated include metformin, insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter-2 inhibitors.

Results

In total, 433 patients with T2DM were included in this study, most of whom were females (55.66% vs 44.34%) and obese (61.20%), with a mean age of 53.29 years (SD ± 15.22). Monotherapy was the most commonly initiated approach (66.28%), with insulin being the most prescribed monotherapy (29.10%). The most frequent combination therapy was metformin and sulfonylureas (7.16%). Overall, the most initiated medication was metformin, accounting for 37.12% of all prescriptions. Additionally, there was an increasing trend in prescribing newer medications, such as GLP-1 receptor agonists (8.70%) and SGLT-2 inhibitors (11.11%), for newly diagnosed patients in 2021.

Conclusion

The initiation of novel antidiabetic medications has increased over the study period, reflecting recent updates in T2DM management guidelines. However, further understanding of their benefits is required for optimal patient care.

查看原文本刊更多论文

沙特阿拉伯NGHA医疗保健系统中2型糖尿病药物的启动：当代趋势

背景：2型糖尿病（T2DM）治疗指南的不断更新影响了治疗模式。在本研究中，我们旨在确定开始使用各种降糖药物的患病率，并根据开始使用的治疗类型分析患者特征的差异。方法：本横断面研究使用国民警卫队卫生事务电子病历中检索的数据，用于2018年1月至2022年5月期间开始任何降糖治疗的所有诊断为T2DM的患者。使用频率、百分比、平均值和标准偏差（如适用）来呈现患者数据。研究的抗糖尿病药物包括二甲双胍、胰岛素、磺脲类药物、噻唑烷二酮类药物、二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白-2抑制剂。结果共纳入T2DM患者433例，以女性（55.66% vs 44.34%）和肥胖（61.20%）居多，平均年龄53.29岁（SD±15.22）。单药治疗是最常见的方法（66.28%），胰岛素是最常用的单药治疗（29.10%）。最常见的联合治疗是二甲双胍和磺脲类药物（7.16%）。总体而言，最开始使用的药物是二甲双胍，占所有处方的37.12%。此外，2021年新诊断患者使用GLP-1受体激动剂（8.70%）和SGLT-2抑制剂（11.11%）等新药的趋势也在增加。在研究期间，新型抗糖尿病药物的使用有所增加，这反映了最近T2DM管理指南的更新。然而，为了获得最佳的患者护理，需要进一步了解它们的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.